Boston Scientific Corp.’s Watchman left-atrial appendage closure device is not only a cost-effective alternative to warfarin or other anticoagulant drugs for patients with atrial fibrillation, but can be cost-saving over time, a new analysis shows.
Vivek Reddy of the Mount Sinai Hospital in New York and colleagues analyzed the cost-effectiveness of reducing stroke risk in patients with atrial fibrillation with Watchman as an alternative to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?